1 JANUARY–30 JUNE 2014 · Order intake rose 7% to SEK 4,832 million (4,525). For comparable units, order intake decreased by 1%. · Net sales rose 8% to SEK 4,680 million (4,331). For comparable units the change was marginal. · Operating profit before amortisation of intangible non-current assets (EBITA) rose 11% to SEK 506 million (455), corresponding to an EBITA margin of 10.8% (10.5%). · Profit after tax rose 14% to SEK 300 million (264). · Earnings per share were SEK 7.50 (6.58). · Cash flow from operating activities amounted to SEK 316 million (294). During the last 12-month period, cash flow per share was SEK 22.03 (17.38). SECOND QUARTER 2014 · Order intake rose 7% to SEK 2,484 million (2,327). For comparable units the change was marginal. · Net sales rose 7% to SEK 2,430 million (2,280). For comparable units the change was marginal. · Operating profit before amortisation of intangible non-current assets (EBITA) rose 7% to SEK 282 million (264), corresponding to an EBITA margin of 11.6% (11.6%). · Profit after tax rose 11% to SEK 174 million (157). · Earnings per share were SEK 4.35 (3.90). · Cash flow from operating activities amounted to SEK 226 million (263). CEO´s MESSAGE While the cautious optimism that existed after the first quarter remains, we have not yet seen any clear trend in the form of a general upswing in demand. The business climate improved somewhat during the second quarter compared with the preceding quarter and corresponding quarter a year ago, but is still characterised by great uncertainty. In addition, order intake for the Group’s companies continues to show considerable variation between months, segments and geographies. Acquisitions are central to the Indutrade Group’s development, and the pace of acquisition increased during the quarter through four completed acquisitions and a total of six since the start of the year. Combined annual sales for the units acquired thus far during the year amount to approximately SEK 350 million. We see that Indutrade’s business model and our company culture fit well in the UK and Ireland, and have therefore consciously increased our acquisition activity there. During the first part of the year we completed four acquisitions in this region. Our goal is to continue growing in these countries, both through additional acquisitions as well as organically, and we consider it realistic to reach sales of minimum SEK 1 billion within a few years. Second quarter Order intake during the quarter exceeded net sales by 2% and was 7% higher than in the corresponding period in 2013. All of the business areas reported order intake in excess of net sales during the quarter, and three of the five business areas had higher order intake for comparable units than the corresponding period a year ago. In the Nordic countries, development was slightly positive in Sweden and essentially unchanged in Norway and Denmark, while demand in Finland was at a continued low level. Outside the Nordic countries, development was positive particularly in the UK and Ireland, and to some degree in Germany and Benelux. Net sales during the past quarter grew 7%. For comparable units the change was marginal. Engineering & Equipment, with operations primarily in Finland, continues to be negatively affected by the low level of domestic industrial activity, and order intake decreased by 8% during the quarter. Flow Technology noted higher order intake also during the second quarter, which was distributed across most segments in the business area. Earnings for the quarter were hurt by somewhat lower gross margins combined with a slight rise in the business area’s overheads. Fluids & Mechanical Solutions experienced positive development during the quarter for most of the business unit’s operations, except for the filters segment, which noted a slight decline. Higher net sales combined with continued good cost control resulted in improved profitability for the quarter. Industrial Components continues to perform very strongly. Order intake grew 16% during the quarter, and growth was both organic and acquisition-driven. Most companies showed growth, particularly in the med-tech, mechanical components and industrial chemical products segments. Earnings improved by 30%, with a good EBITA margin. Special Products’ total order intake rose 7% despite negative organic growth, owing to a decrease in project-based orders in Switzerland during the quarter. It is gratifying to note that order intake for the energy segment recovered following a couple of weak quarters. Most other businesses noted a slight improvement in order intake at the same time that recently acquired units continued to develop according to plan. The earnings increase during the quarter came mostly from completed acquisitions. This was counteracted by a poorer mix, i.e., sales with high margins have been replaced by volumes from businesses with lower margins, resulting in a lower EBITA margin for the quarter. Margins The Group’s gross margin remains stable at 34% (34%). The EBITA margin was 11.6% for the quarter (11.6%), which is higher than the Group’s target of a minimum 10% EBITA margin over a business cycle. Acquisitions Four acquisitions were carried out in the UK during the quarter: CRP Ltd, which specialises in corrosion-resistant piping, valves and expansion bellows; Micro Spring and Presswork Ltd, which manufactures industrial springs and stampings; Birmingham Specialities Ltd, a specialist manufacturer of industrial components; and ALH Systems Ltd, a specialist in encapsulants, sealants and adhesives. Outlook The trend we have seen during the first half of the year will likely continue during the coming autumn, i.e., some growth in a number of segments and in certain geographical areas. Our ambition is, according to Indutrade’s business model, to continue acquiring companies during the autumn. Johnny Alvarsson, President and CEO For further information, please contact: Johnny Alvarsson, President and CEO: 46 70 589 17 95 About Indutrade Indutrade markets and sells components, systems and services with a high-tech content within selected niches. Indutrade's business is distinguished by - high-tech products for recurring needs - growth through a structured and tried-and tested acquisition strategy - a decentralised organisation characterised by an entrepreneurial spirit. The Group is organised into five business areas: Engineering & Equipment, Flow Technology, Fluids & Mechanical Solutions, Industrial Components and Special Products. Indutrade's sales totalled SEK 8,831 million in 2013, generating operating income of SEK 990 million before depreciation of intangible assets. Indutrade is listed on the Nasdaq OMX Stockholm.
Interim report 1 January-30 June 2014 1 JANUARY–30 JUNE
Top 10 Most Recent News Articles
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026
A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...
Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss
Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...
Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake
Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...
Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control
Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...
Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data
Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...
Continue Reading
Uber Data Breach: Class Action Investigation Begins
When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...
Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives
Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...
Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle
IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...
Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path
New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...
Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit
High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...
Continue ReadingTop 5 Most Recently Viewed Articles
Kulicke & Soffa Announces Conference Call for Fiscal Results
Kulicke & Soffa Schedules Conference Call Kulicke and Soffa Industries, Inc. (NASDAQ: KLIC), a leading name in semiconductor assembly technology, has announced a conference call to discuss its third fiscal quarter financial results and business outlook. The call is set for a future date, highlighting the company's commitment to transparency and communication with its...
Continue Reading
ARMOUR Residential REIT Launches Major Stock Offering for Growth
ARMOUR Residential REIT Enters Public Stock Offering ARMOUR Residential REIT, Inc. (NYSE: ARR and ARR-PRC) has officially announced an underwritten public offering of 18,500,000 shares of common stock. The company is poised to grant underwriters an additional option to purchase up to 2,775,000 shares, making this a significant move for ARMOUR as it aims to enhance its...
Continue Reading
Celebrate Mother's Day with a Unique Brunch at Cannon + Belle
Cannon + Belle Offers a Memorable Mother's Day Brunch Cannon + Belle at Hilton Austin is excited to announce an elevated Mother's Day brunch that promises to create unforgettable memories. This year, the restaurant will be hosting a special brunch event aimed at honoring mothers and all they do. With an impressive menu curated by the talented Chef Gereamy Cater, guests...
Continue Reading
Figma's Shares Surge in IPO But Valuation Remains a Concern
Figma's Impressive IPO Performance Figma Inc. (NYSE: FIG) has captured significant investor attention following its explosive debut in the stock market. After launching its initial public offering, the company's shares skyrocketed by over 250%, marking a remarkable milestone for the firm. The stock began trading at a price of $33 per share, leading to approximately $1.2...
Continue Reading
Journey Medical Corporation's Emrosi Launch for Rosacea Relief
Journey Medical Corporation Introduces Emrosi for Rosacea Treatment Journey Medical Corporation, a key player in the dermatological pharmaceutical industry, has recently launched Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules), designed for the effective treatment of rosacea. The product, featuring a unique formulation of 10 mg immediate release and...
Continue Reading